PubRank

Ipilimumab and Gemcitabine Hydrochloride in Treating Patients With Stage III-IV or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery

Clinical Trial ID NCT01473940

PubWeight™ 12.02‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01473940

Top papers

Rank Title Journal Year PubWeight™‹?›
1 At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy. J Leukoc Biol 2013 1.90
2 Cancer immunotherapy in clinical practice -- the past, present, and future. Chin J Cancer 2014 0.98
3 Novel antibodies targeting immune regulatory checkpoints for cancer therapy. Br J Clin Pharmacol 2013 0.94
4 Immune checkpoint blockade in cancer treatment: a double-edged sword cross-targeting the host as an "innocent bystander". Toxins (Basel) 2014 0.92
5 Novel approaches in the management of pancreatic ductal adenocarcinoma: potential promises for the future. J Hematol Oncol 2015 0.91
6 Advances in the management of gastrointestinal cancers--an upcoming role of immune checkpoint blockade. J Hematol Oncol 2015 0.91
7 From bench to bedside a comprehensive review of pancreatic cancer immunotherapy. J Immunother Cancer 2016 0.90
8 Advanced pancreatic cancer: flourishing novel approaches in the era of biological therapy. Oncologist 2014 0.87
9 Systemic Chemotherapy in Advanced Pancreatic Cancer. Gut Liver 2016 0.81
10 Molecular signature of pancreatic adenocarcinoma: an insight from genotype to phenotype and challenges for targeted therapy. Expert Opin Ther Targets 2015 0.81
11 Immune checkpoint therapy for pancreatic cancer. World J Gastroenterol 2016 0.79
12 Have lessons from past failures brought us closer to the success of immunotherapy in metastatic pancreatic cancer? Oncoimmunology 2015 0.78
13 Immune checkpoint and inflammation as therapeutic targets in pancreatic carcinoma. World J Gastroenterol 2016 0.75
Next 100